Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment. The purpose of this study is to find out if the common dietary supplement Vitamin B3 could allow drugs that kill bacteria to not negatively affect treatments that mobilize the immune system to fight tumors.

Trial Details

NCT ID
NCT07119996
Phase
PHASE1
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • The patient voluntarily agrees to participate, is able to provide written informed consent, and is willing and able to comply with the protocol and…
  • Aged ≥18 years on the date of signing the informed-consent form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix 1).
  • Residual tumour after TURBT and histologically confirmed urothelial carcinoma of the bladder staged cT2-T4a N0 M0 by AJCC 8th edition imaging; for …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →